{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shah S"],"funding":["NIDA NIH HHS","National Institute on Drug Abuse"],"pagination":["2457-2461"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10940736"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["78(10)"],"pubmed_abstract":["<h4>Objectives</h4>The incidence of Serratia endocarditis is increasing, yet optimal treatment has not been defined. Our objective was to investigate the outcomes of patients with Serratia endocarditis by treatment strategy.<h4>Methods</h4>We reviewed adult patients with definitive Serratia endocarditis at two independent health systems between July 2001 and April 2023. Combination therapy was defined as receipt of ≥2 in vitro active agents for ≥72 h.<h4>Results</h4>Seventy-five patients were included; 64% (48/75) were male and 85% (64/75) were people who inject drugs. Compared with monotherapy, receipt of combination therapy was associated with lower rates of microbiological failure (0% versus 15%, P = 0.026) and 90 day all-cause mortality (11% versus 31%, P = 0.049). Antimicrobial discontinuation due to an adverse event was more common among patients receiving combination therapy compared with monotherapy (36% versus 8%, P = 0.058).<h4>Conclusions</h4>In the largest series of Serratia endocarditis to date, combination antibiotic treatment was associated with improved outcomes. However, larger, prospective studies are warranted."],"journal":["The Journal of antimicrobial chemotherapy"],"pubmed_title":["Serratia endocarditis: antimicrobial management strategies and clinical outcomes."],"pmcid":["PMC10940736"],"funding_grant_id":["K23DA049946","K23 DA049946"],"pubmed_authors":["McCrary M","Shields RK","Davis MW","Schranz AJ","Shah S","Topal J","Slain D","Marx A","Clarke L","Stoner BJ"],"additional_accession":[]},"is_claimable":false,"name":"Serratia endocarditis: antimicrobial management strategies and clinical outcomes.","description":"<h4>Objectives</h4>The incidence of Serratia endocarditis is increasing, yet optimal treatment has not been defined. Our objective was to investigate the outcomes of patients with Serratia endocarditis by treatment strategy.<h4>Methods</h4>We reviewed adult patients with definitive Serratia endocarditis at two independent health systems between July 2001 and April 2023. Combination therapy was defined as receipt of ≥2 in vitro active agents for ≥72 h.<h4>Results</h4>Seventy-five patients were included; 64% (48/75) were male and 85% (64/75) were people who inject drugs. Compared with monotherapy, receipt of combination therapy was associated with lower rates of microbiological failure (0% versus 15%, P = 0.026) and 90 day all-cause mortality (11% versus 31%, P = 0.049). Antimicrobial discontinuation due to an adverse event was more common among patients receiving combination therapy compared with monotherapy (36% versus 8%, P = 0.058).<h4>Conclusions</h4>In the largest series of Serratia endocarditis to date, combination antibiotic treatment was associated with improved outcomes. However, larger, prospective studies are warranted.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Oct","modification":"2026-03-17T16:15:18.625Z","creation":"2025-08-21T09:50:33.818Z"},"accession":"S-EPMC10940736","cross_references":{"pubmed":["37563876"],"doi":["10.1093/jac/dkad254"]}}